Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy

NCT03410056 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03410056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03410056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Terminated
Start date
May 22, 2018
Completion date
May 13, 2020
Enrollment
36 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis ra